Carmelo Magnano

TL;DR: A comparative phase 3 trial was conducted to demonstrate the efficacy of deferasirox in regularly transfused patients with beta-thalassemia aged 2 years or older, and found it to be a promising once-daily oral therapy for the treatment of transfusional iron overload.

TL;DR: The results of this study show that the risk factors for predicting mortality in patients with thalassemia major are deferoxamine-treatment, complications, and the interaction effect of sex and age.

TL;DR: Transfusion-dependent thalassemics have mild liver necroinflammation, mainly attributable to HCV infection, and its progression is mostly influenced by iron overload which, with current therapy regimens, may be attributable to both erythrocyte catabolism and iron hyperabsorption.

TL;DR: The trial results show that sequential DFP–DFO treatment compared with DFP alone significantly decreased serum ferritin concentration during treatment for 5’years without significant differences regarding survival, adverse events, or costs.

TL;DR: More than 25% of infections resolve within 6 years; the presence of anti-E2 seems to be protective against infection.